This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Axonics Past Earnings Performance

Past criteria checks 0/6

Axonics has been growing earnings at an average annual rate of 28.1%, while the Medical Equipment industry saw earnings growing at 13.2% annually. Revenues have been growing at an average rate of 41.3% per year.

Key information

28.1%

Earnings growth rate

38.0%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate41.3%
Return on equity-0.9%
Net Margin-1.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Axonics' Market Growth Strengthens Boston Scientific's Future

Nov 05

A Look At The Fair Value Of Axonics, Inc. (NASDAQ:AXNX)

Jul 14
A Look At The Fair Value Of Axonics, Inc. (NASDAQ:AXNX)

Axonics, Inc.'s (NASDAQ:AXNX) Earnings Haven't Escaped The Attention Of Investors

Jun 20
Axonics, Inc.'s (NASDAQ:AXNX) Earnings Haven't Escaped The Attention Of Investors

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 21% Discount?

Mar 27
Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 21% Discount?

Here's Why We're Not At All Concerned With Axonics' (NASDAQ:AXNX) Cash Burn Situation

Feb 28
Here's Why We're Not At All Concerned With Axonics' (NASDAQ:AXNX) Cash Burn Situation

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 32% Discount?

Nov 28
Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 32% Discount?

Axonics stock falls 5.6% after Needham downgrades rating

Oct 10

Axonics Stock Is A Buy Amid Current Capex Cycle

Sep 07

Axonics prices stock offering of 1.75M shares

Aug 03

Companies Like Axonics (NASDAQ:AXNX) Can Afford To Invest In Growth

Aug 02
Companies Like Axonics (NASDAQ:AXNX) Can Afford To Invest In Growth

Axonics: A Strong Medical Device Play With Significant Revenue Growth Opportunities

May 30

Axonics (NASDAQ:AXNX) Is In A Strong Position To Grow Its Business

Apr 19
Axonics (NASDAQ:AXNX) Is In A Strong Position To Grow Its Business

Revenue & Expenses Breakdown

How Axonics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:AXNX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24432-628247
30 Jun 24409-226542
31 Mar 24387-1625238
31 Dec 23366-623535
30 Sep 23343-1222333
30 Jun 23320-3221333
31 Mar 23296-4620831
31 Dec 22274-6019634
30 Sep 22241-7618136
30 Jun 22217-7716837
31 Mar 22194-8015139
31 Dec 21180-8013637
30 Sep 21162-7612135
30 Jun 21150-6810934
31 Mar 21120-639532
31 Dec 20112-559229
30 Sep 2087-668927
30 Jun 2053-828724
31 Mar 2039-818223
31 Dec 1914-806820
30 Sep 194-675119
30 Jun 193-493418
31 Mar 192-392119
31 Dec 181-321319
30 Sep 180-281018
30 Jun 180-25717
31 Mar 180-20614
31 Dec 170-18612

Quality Earnings: AXNX is currently unprofitable.

Growing Profit Margin: AXNX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AXNX is unprofitable, but has reduced losses over the past 5 years at a rate of 28.1% per year.

Accelerating Growth: Unable to compare AXNX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AXNX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.7%).


Return on Equity

High ROE: AXNX has a negative Return on Equity (-0.85%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/11/14 12:44
End of Day Share Price 2024/11/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Axonics, Inc. is covered by 9 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Travis SteedBarclays
Travis SteedBofA Global Research
Christopher PasqualeGuggenheim Securities, LLC